Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) Leases (2022 - 2026)

Cytek Biosciences filings provide 4 years of Leases readings, the most recent being $11.3 million for Q4 2025.

  • On a quarterly basis, Leases rose 11.28% to $11.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.3 million, a 11.28% increase, with the full-year FY2025 number at $11.3 million, up 11.28% from a year prior.
  • Leases hit $11.3 million in Q4 2025 for Cytek Biosciences, up from $11.2 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $16.4 million in Q2 2025 to a low of $9.3 million in Q2 2024.
  • Median Leases over the past 4 years was $11.5 million (2023), compared with a mean of $12.0 million.
  • Biggest five-year swings in Leases: decreased 24.91% in 2024 and later soared 75.68% in 2025.
  • Cytek Biosciences' Leases stood at $13.9 million in 2022, then dropped by 21.83% to $10.9 million in 2023, then fell by 6.31% to $10.2 million in 2024, then increased by 11.28% to $11.3 million in 2025.
  • The last three reported values for Leases were $11.3 million (Q4 2025), $11.2 million (Q3 2025), and $16.4 million (Q2 2025) per Business Quant data.